Goldamit (Citalopram)

Goldamit (citalopram) is primarily prescribed for the treatment of major depressive disorder and may be considered in related mood conditions.

• Management of major depressive disorder in adults.
• Adjunctive therapy for persistent depressive symptoms when first‑line treatment is insufficient.
• Off‑label use for anxiety disorders under clinical supervision.
• May be used in the continuation phase to prevent relapse after acute response.
• Treatment of depressive episodes in bipolar disorder under specialist supervision.
• May be considered for obsessive‑compulsive disorder when other options are ineffective.

Side effects of Goldamit vary in frequency and severity; they are categorized as common or serious, and patients should be aware of both typical and rare reactions.

Common

• Nausea or upset stomach.
• Dry mouth.
• Drowsiness or fatigue.
• Insomnia or vivid dreams.
• Sweating.
• Sexual dysfunction such as decreased libido.
• Headache.
• Dizziness.

Serious

• Serotonin syndrome (agitation, rapid heart rate, high blood pressure).
• Severe allergic reaction (rash, swelling, difficulty breathing).
• QT interval prolongation leading to cardiac arrhythmia.
• Suicidal thoughts, especially in young adults.
• Severe hyponatremia (low sodium levels).
• Cardiac arrhythmias requiring medical attention.

Before starting Goldamit, healthcare providers assess several safety considerations to minimize risks and ensure appropriate monitoring throughout treatment.

• Evaluate history of bipolar disorder or mania.
• Review any previous serotonin syndrome episodes.
• Assess liver or kidney impairment that may affect drug clearance.
• Consider pregnancy, breastfeeding, and potential fetal risk.
• Monitor for worsening depression or emergence of suicidal thoughts.
• Use caution in patients taking other QT‑prolonging agents.
• Review concomitant use of over‑the‑counter supplements that may affect serotonin levels (e.g., St. John’s wort).

Goldamit can interact with other medicines; some combinations should be avoided while others require careful monitoring to prevent adverse effects.

Avoid

• Monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI.
• Other serotonergic agents such as tramadol, linezolid, or certain migraine medications.
• Drugs known to prolong the QT interval (e.g., certain antiarrhythmics).
• Certain antifungal agents (e.g., ketoconazole) that increase citalopram levels.

Use with caution

• Anticoagulants like warfarin (may increase bleeding risk).
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can affect platelet function.
• Alcohol, which may enhance drowsiness.
• Anticonvulsants such as carbamazepine that may reduce citalopram efficacy.
• Other QT‑prolonging medications under close cardiac monitoring.